DE-INCYTE
21.8.2024 17:41:34 CEST | Business Wire | Press release
Incyte (Nasdaq: INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2024, to be held September 13-17 in Barcelona and virtually.
"The data at ESMO underscore the progress across our oncology portfolio and the potential to impact patients where additional treatment options are needed. Notably, a Presidential Symposium will feature new, pivotal results from the Phase 3 POD1UM-303/InterAACT2 study of retifanlimab (Zynyz®) for the treatment of squamous cell anal carcinoma (SCAC). The POD1UM-303 data will support the supplemental Biologics License Application (sBLA) filing for retifanlimab in SCAC planned by year end 2024," said Pablo Cagnoni M.D., President, Head of Research and Development, Incyte. "We will also present new data on INCB123667, a potential first-in-class CDK2 inhibitor, which we believe has the potential to enhance outcomes and serve as a foundational treatment for platinum-resistant ovarian and other cancers."
Details on the abstracts accepted for presentation at ESMO include:
Presidential Symposium
Retifanlimab (PD-1)
POD1UM-303/InterAACT2: Phase 3 Study of Retifanlimab With Carboplatin-Paclitaxel (C-P) in Patients (Pts) With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal (SCAC) Not Previously Treated With Systemic Chemotherapy
Presidential Symposium I: Practice-changing trials. Presentation Number: LBA2. Presentation Time: 10:50-11:02 a.m. ET (4:50-5:02 p.m. CET), September 14, 2024
Mini Oral Session
INCB123667
Safety and Tolerability of INCB123667, a Selective CDK2 Inhibitor, in Patients (Pts) With Advanced Solid Tumors: A Phase 1 Study
Mini oral session: Developmental therapeutics. Presentation Number: 617MO. Presentation Time: 9:35 – 9:40 a.m. ET (3:35-3:40 p.m. CET), September 14, 2024
Conference Call and Webcast
Incyte will host an in-person analyst and investor event on Saturday, September 14, 2024, from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST) to discuss key data presentations at ESMO including data from the POD1UM-303 Presidential Symposia and its CDK2 inhibitor program. The CDK2 data presentation will include new results from a later data cut-off, as well as the data included in the ESMO accepted abstract and mini-oral presentation. The event will be webcasted and can be accessed via the Events and Presentations tab of the Investor section of Incyte.com and it will be available for replay for 90 days.
Conference call details will be provided on the Investor section of Incyte.com.
Abstracts will be available to registered attendees on the ESMO Virtual Congress platform beginning on September 9, 2024. All accepted abstracts will be published in the ESMO Congress 2024 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
More information regarding the 2024 ESMO Congress can be found at https://www.esmo.org/meeting-calendar/esmo-congress-2024.
About Retifanlimab (Zynyz®)
Retifanlimab (Zynyz®), is an intravenous PD-1 inhibitor indicated in the U.S. for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Zynyz is marketed by Incyte in the U.S. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab.
Zynyz is a trademark of Incyte.
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, the potential for retifanlimab and INCB123667 to positively impact patients and plans to submit an sBLA for retifanlimab in SCAC by year end 2024, contain predictions, estimates, and other forward-looking statements.
These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and regulatory agencies outside of the United States; the efficacy or safety of our products; the acceptance of our products in the marketplace; market competition; unexpected variations in the demand for our products and the products of our collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products; sales, marketing, manufacturing, and distribution requirements, including our ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional new products that become approved; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended June 30, 2024. We disclaim any intent or obligation to update these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821420609/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hytera Debuts SC700 Smart 4G Body Camera at CCW 202630.6.2026 11:30:00 CEST | Press release
Hytera, a leading global provider of critical communications technologies and solutions, officially debuted its SC700 Smart 4G Body Camera at Critical Communications World (CCW) 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630283236/en/ Hytera's latest SC700 Smart 4G Body Camera Public safety operations are increasingly moving toward real-time, connected workflows, where communication, video, and situational awareness are integrated to support a faster and more coordinated response in the field. The SC700 is designed to support this shift. It enables live video, location sharing and push-to-talk communication, helping connect frontline officers with control rooms. Integrated with Hytera HyTalk PoC System, it also supports communication across broadband and PMR users to improve coordination across teams. It also features Intelligent Scene Aware, which can detect abnormal situations such as man down, inactivity, or
Global Database Launches Regis, an AI Assistant for Live Company Registry Data30.6.2026 11:13:00 CEST | Press release
Regis gives business users a ChatGPT-like experience for company research, compliance checks, ownership discovery, financial analysis, and prospect list building — powered by live data from official government registries Global Database today announced the launch of Regis, a new AI assistant designed to answer business questions using live company data from official government registries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630229011/en/ Unlike general-purpose AI tools that rely on training data or open web sources, Regis is connected to Global Database’s structured company intelligence platform, covering more than 600 million company profiles, sourced from over 400 government registries across more than 200 countries. For more than a decade, Global Database has been collecting, structuring, and maintaining company data directly from government registries around the world. With the launch of Regis, the company
Kraken Goes Live on Trever to Bring Full-Service Prime Brokerage to European Financial Institutions30.6.2026 10:30:00 CEST | Press release
European banks, brokers and other licensed financial institutions using Trever can now access Kraken Prime’s institutional crypto trading and qualified custody Kraken Prime, the full-service prime brokerage offering trading, qualified custody and other financial services through an integrated platform, is now available through Trever, the operating standard in digital asset banking. Trever’s Digital Asset Operating System is used by financial institutions across Europe to manage the full digital asset lifecycle within a single environment – including trading, treasury, settlement and bookkeeping. From today, banks and brokers using Trever can route execution, settle into qualified custody, record all transactions and access other services through Kraken Prime without leaving their existing operational environment. The integration extends Trever’s connectivity, bringing a prime brokerage relationship into the existing workflows institutional teams use across their digital asset operatio
Microsoft Takes Sisvel Wi-Fi Multimode Patent Pool Licence30.6.2026 10:17:00 CEST | Press release
Microsoft has become a licensee of the Sisvel Wi-Fi Multimode pool. The US computer and software giant is the latest in a string of major companies to take a licence to the standard essential patents offered through the programme. In doing so, it joins ASUS, Hewlett Packard Enterprise and Sony Group Corporation, as well as Huawei, Panasonic, Philips and ZTE which are also pool licensors alongside KPN, Mitsubishi Electric, Orange, Aegis 11 (a Sisvel affiliate), SK Telecom and Wilus. The Sisvel Wi-Fi Multimode pool covers both Wi-Fi 6 and Wi-Fi 7 and offers an efficient way to access essential Wi-Fi rights for years to come. It was publicly launched in January 2026 as the successor to the Sisvel Wi-Fi 6 patent pool. Over a three-year period under that programme, agreements were closed with 40 companies, including Acer, Netgear, Cisco and HP. “It is a pleasure to welcome Microsoft as a licensee of the Sisvel Wi-Fi Multimode pool,” says Alex Debski, Director of Licensing and Counsel Legal
STOKR Secures CASP and PI Licences in Luxembourg Ahead of MiCAR Deadline30.6.2026 10:00:00 CEST | Press release
Authorised by the CSSF just before the 1 July 2026 enforcement deadline, STOKR joins a small group of crypto-asset firms cleared to operate across the EU under a single, harmonised regime. STOKR, the Luxembourg-based digital securities platform, has received authorisation from the Commission de Surveillance du Secteur Financier (CSSF) under the EU's Markets in Crypto-Assets Regulation (MiCAR) and the Law of 10 November 2009 on payment services, securing its Crypto-Asset Service Provider (CASP) and Payment Institution (PI) licences just over a week before MiCAR's 1 July 2026 enforcement deadline. Digital securities fall outside MiCAR's scope but the payment leg does not. To receive, hold, and transfer crypto assets and stablecoins on behalf of clients during subscription and redemption, a platform requires a CASP licence under MiCAR and a PI. Without both, a platform can issue digital securities but cannot move the capital. With MiCAR's transitional period ending on 30 June 2026, a sign
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom